Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G

被引：2

作者：

Sugimoto, Naotoshi

Sakai, Daisuke

Tamura, Takao

Hara, Hiroki

Nishina, Tomohiro

Esaki, Taito

Okuda, Hiroyuki

Denda, Tadamichi

Tsuda, Masahiro

Satoh, Taroh

Makiyama, Akitaka

Yamazaki, Kentaro

Kuramochi, Hidekazu

Hosokawa, Ayumu

Tsuda, Takashi

Taniguchi, Hiroya

Kishimoto, Junji

Boku, Narikazu

Hyodo, Ichinosuke

Muro, Kei

机构：

[1] Osaka Med Ctr Canc & Cardiovasc Dis, Gastrointestinal Oncol, Osaka, Japan

[2] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan

[3] Kinki Univ, Osaka, Japan

[4] Saitama Canc Ctr Hosp, Dept Gastroenterol, Saitama, Japan

[5] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[6] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Fukuoka, Japan

[7] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[8] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan

[9] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan

[10] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan

[11] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan

[12] Tokyo Womens Med Univ, Yachiyo Med Ctr, Yachiyoshi, Chiba, Japan

[13] Toyama Univ, Dept Gastroenterol & Hematol, Fac Med, Toyama, Japan

[14] St Marianna Univ Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan

[15] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[16] Kyushu Univ, Fukuoka, Fukuoka, Japan

[17] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo, Japan

[18] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki, Japan

[19] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期

关键词：

D O I：

10.1200/JCO.2017.35.4_suppl.661

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

661

引用

页数：2

共 50 条

[21] Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (541.1) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase
Souglakos, J
Ziras, N
Polyzos, A
Athanasiadis, A
Kakolyris, S
Giannakakis, T
Tselepatiotis, E
Kalbakis, K
Vardakis, N
Georgoulias, V
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 253S - 253S
[22] Irinotecan (CPT-11) plus raltitrexed as second line chemotherapy (CT) in metastatic colorectal cancer: A phase II study. Preliminary results.
Caroti, C
Aschele, C
Mammoliti, S
D'Amico, M
Torrisi, R
Gallo, L
ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
[23] A phase I trial of intraperitoneal (IP) chemohyperthermia (CH) with oxaliplatin (L-OHP) and irinotecan (CPT-11) in patients (pts) with peritoneal carcinomatosis (PC): Pharmacokinetic (PK), tissue distribution and tolerance.
Ducreux, M
Boige, V
Pocard, M
Lasser, P
Malka, D
Bonnay, M
Magherini, E
Oprea, C
Elias, D
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 287S - 287S
[24] A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
Saridaki, Z.
Androulakis, N.
Vardakis, N.
Vamvakas, L.
Kabouraki, E.
Kalbakis, K.
Hatzidaki, D.
Voutsina, A.
Mavroudis, D.
Georgoulias, V.
Souglakos, J.
BRITISH JOURNAL OF CANCER, 2012, 107 (12) : 1932 - 1937
[25] A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
Z Saridaki
N Androulakis
N Vardakis
L Vamvakas
E Kabouraki
K Kalbakis
D Hatzidaki
A Voutsina
D Mavroudis
V Georgoulias
J Souglakos
British Journal of Cancer, 2012, 107 : 1932 - 1937
[26] Appropriate schedule of oral tegafur / uracil (UFT) in combination with irinotecan (CPT-11) and bolus 5-FU / l-leucovorin (LV) in patients (pts) with metastatic colorectal cancer (MCRC): A phase I study
Chayahara, N.
Tamura, T.
Miki, I.
Okuno, T.
Kamigaki, T.
Nishisaki, H.
Inoue, Y.
Maeda, T.
Sakaeda, T.
Azuma, T.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[27] Predictive value of primary tumor location: Results from randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)
Tamura, T.
Sakai, D.
Sugimoto, N.
Tokunaga, S.
Tsuji, A.
Ishida, H.
Otsu, S.
Moriwaki, T.
Satake, H.
Uchino, K.
Matsumoto, S.
Baba, E.
Sato, M.
Taniguchi, H.
Kishimoto, J.
Boku, N.
Hyodo, I.
Muro, K.
ANNALS OF ONCOLOGY, 2017, 28
[28] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
Eng, C.
Bendell, J. C.
Bessudo, A.
Gabrail, N. Y.
Diamond, J.
Pande, A. U.
Gorbatchevsky, I.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[29] Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients
Koji Okabayashi
Hirotoshi Hasegawa
Yoshiyuki Ishii
Takashi Endo
Hiroki Ochiai
Tetsuro Kubota
Yuko Kitagawa
Cancer Chemotherapy and Pharmacology, 2009, 63 : 501 - 507
[30] Prospective evaluation of patients' preferences of three different regimens in a phase II study of FU, oxaliplatin, mitomycin C and CPT-11 in advanced colorectal cancer.
Guglielmi, A
Cirillo, M
Mammoliti, S
Fornarini, G
Caroti, C
Sobrero, A
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 308S - 308S

← 1 2 3 4 5 →